JOSD2 and non-small cell lung carcinoma: Over-expressed JOSD2 was positively correlated with the worse prognosis in hepatocellular carcinoma (Huang et al., 2022), cholangiocarcinoma (CCA) (Qian et al., 2021), and NSCLC (Krassikova et al., 2021).